We Give Shareholders a Voice
Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Bioverativ Inc. (NASDAQGS: BIVV) to Sanofi for $105 per share.
The investigation concerns whether the Board of Bioverativ breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Sanofi is underpaying for Bioverativ shares, thus unlawfully harming Bioverativ shareholders.
To receive more information, please fill out the form.